Alnylam Pharmaceuticals Inc. | Large-cap | Healthcare
$325.00
3.79%
| Alnylam Stock Comparison:
Alnylam vs VertexAlnylam vs RegeneronAlnylam vs Royalty Pharma plcAlnylam vs InsmedAlnylam vs IncyteAlnylam vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2.2B
Gross Profit 1.9B 85.62%
Operating Income -176.9M -7.87%
Net Income -278.2M -12.37%

Balance Sheet Metrics

Total Assets 4.2B
Total Liabilities 4.2B
Shareholders Equity 67.1M
Debt to Equity 62.20

Cash Flow Metrics

Operating Cash Flow -185.3M
Free Cash Flow -42.6M

Revenue & Profitability Trend

Alnylam Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 2.2B 1.8B 1.0B 844.3M 492.9M
Cost of Goods Sold 323.4M 310.4M 168.8M 140.1M 78.1M
Gross Profit 1.9B 1.5B 868.6M 704.1M 414.8M
Operating Expenses 2.1B 1.8B 1.7B 1.4B 1.2B
Operating Income -176.9M -282.2M -785.1M -708.7M -828.4M
Pre-tax Income -377.4M -433.5M -1.1B -852.1M -855.6M
Income Tax -99.2M 6.7M 4.2M 680.0K 2.7M
Net Income -278.2M -440.2M -1.1B -852.8M -858.3M
EPS (Diluted) - -$3.52 -$9.30 -$7.20 -$7.46

Income Statement Trend

Alnylam Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 3.3B 3.0B 2.7B 2.8B 2.6B
Non-Current Assets 944.7M 847.2M 854.1M 834.7M 792.3M
Total Assets 4.2B 3.8B 3.5B 3.6B 3.4B
Liabilities
Current Liabilities 1.2B 967.8M 767.9M 695.7M 585.3M
Non-Current Liabilities 3.0B 3.1B 2.9B 2.4B 1.8B
Total Liabilities 4.2B 4.1B 3.7B 3.1B 2.4B
Equity
Total Shareholders Equity 67.1M -220.6M -158.2M 588.2M 1.0B

Balance Sheet Composition

Alnylam Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -278.2M -440.2M -1.1B -852.8M -858.3M
Operating Cash Flow -185.3M 5.2M -707.3M -592.3M -573.9M
Investing Activities
Capital Expenditures -34.3M -62.2M -72.1M -76.4M -70.4M
Investing Cash Flow -116.8M -336.4M 169.4M -273.3M -435.5M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -8.8M 24.7M 166.4M 1.0B 794.5M
Free Cash Flow -42.6M 41.9M -613.3M -718.1M -685.3M

Cash Flow Trend

Alnylam Key Financial Ratios

Valuation Ratios

Forward P/E -256.66
Price to Book 353.42
Price to Sales 17.39
PEG Ratio -256.66

Profitability Ratios

Profit Margin -11.49%
Operating Margin 3.04%
Return on Equity -414.62%
Return on Assets -1.79%

Financial Health

Current Ratio 3.04
Debt to Equity 2,358.26
Beta 0.21

Per Share Data

EPS (TTM) -$2.10
Book Value per Share $0.89
Revenue per Share $18.27

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
alny 40.8B - 353.42 -414.62% -11.49% 2,358.26
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Royalty Pharma plc 20.3B 14.75 2.30 18.00% 48.26% 77.82
Insmed 20.0B - 193.43 -320.20% -265.93% 1,316.96
Incyte 13.0B 336.30 3.55 0.47% 0.48% 1.18

Financial data is updated regularly. All figures are in the company's reporting currency.